Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Revenue projections:

Revenue projections for JUBLPHARMA
Revenue projections for JUBLPHARMA

JUBLPHARMA is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 1.656000
forwardPE 22.417011
debtToEquity 43.867000
earningsGrowth 0.172000
revenueGrowth 0.122000
grossMargins 0.654230
operatingMargins 0.120320
trailingEps 30.100000
forwardEps 0.000000

JUBLPHARMA's current ratio of 1.656, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as JUBLPHARMA has enough cash and current assets to handle its immediate liabilities comfortably.
JUBLPHARMA's Forward PE ratio is in a good range, reflecting a reasonable balance between stock price and earnings. The stock is not overpriced, leaving room for growth, which suggests potential for investors looking to capitalize on future value appreciation.
JUBLPHARMA's positive earnings and revenue growth indicate that the company is expected to continue expanding its business. These trends reflect strong financial health, with increasing profits and sales suggesting sustained growth and success for JUBLPHARMA.

Price projections:

Price projections for JUBLPHARMA
Price projections for JUBLPHARMA

JUBLPHARMA's present price relative to projections does not indicate any obvious risks or opportunities. This balanced situation suggests a period of stability, where investors may find it prudent to maintain their current strategies until more information becomes available.

Insider Transactions:

Insider Transactions for JUBLPHARMA
Insider Transactions for JUBLPHARMA


4 transactions to buy JUBLPHARMA took place, with market price at 1068.9750061035156 per share.No buy transactions occurred in the period under review.The increased selling activity around JUBLPHARMA's current price levels may indicate further downside risk. If this trend continues, the stock's price could face additional declines as selling pressure intensifies.

Recommendation changes over time:

Recommendations trend for JUBLPHARMA
Recommendations trend for JUBLPHARMA


JUBLPHARMA has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see JUBLPHARMA as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.